Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

119P - Prospective trial of immuno-(chemo)therapy (IO) prior to resection, definitive chemo-radiotherapy, or palliative therapy in patients with borderline resectable non-small cell lung cancer (NSCLC) including oligometastatic disease (KOMPASSneo)


31 Mar 2023


Poster Display session


Martin Faehling


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


M. Faehling1, K. Lehrach2, S. Fallscheer2, B. Schwenk2, S. Kramberg2, J. Sträter3, S. Eschmann4, M. Hetzel5, F. Heinzelmann6, R. Sätzler2

Author affiliations

  • 1 Esslingen am Neckar/DE
  • 2 Klinikum Esslingen, Esslingen am Neckar/DE
  • 3 Institut für Pathologie, Esslingen am Neckar/DE
  • 4 Marienhospital Stuttgart, Stuttgart/DE
  • 5 Krankenhaus vom Roten Kreuz, Stuttgart/DE
  • 6 Klinikum Esslingen, 73730 - Esslingen am Neckar/DE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 119P


Recent trials of IO prior to resection in locally advanced NSCLC report high rates of pathological response. However, primarily irresectable patients were excluded from most studies. Moreover, there is no data on chemo-radiotherapy (CRT) after IO in patients who are primarily not amenable to CRT. We hypothesized that induction IO may enable more NSCLC patients to receive curative treatment.


We enrolled 78 patients with borderline resectable NSCLC including oligometastatic disease into a prospective real-world trial of induction IO followed by morphologic and metabolic reassessment and multidisciplinary board-guided curative treatment (resection [preferred] or CRT) or palliative therapy. 1° endpoint was the proportion of patients completing curative treatment. 2° endpoints included response and survival. Furthermore, pathological response was assessed in resected patients. Exploratory endpoints included the predictive role of PD-L1-TPS and the TP53-mutation status.


73 patients (94%) received curative treatment (32 complete resections, 41 CRT). 18 (56%) of resected patients had a major pathological response including 13 (41%) with pathological complete response. In curatively treated patients, there were 23 recurrences (32%) and 15 tumor-related deaths (21%): 5 recurrences (16%) and no deaths in resected patients, and 18 recurrences (44%) and 15 (37%) deaths in CRT-patients (median follow-up 18 months). There were two treatment-related deaths (one postoperative due to sepsis, one after CRT due to pneumonitis). Patients with high PD-L1-TPS had deeper pathological response and longer survival. Resected patients with TP53-mutation had poorer pathological response and numerically more recurrences than those without TP53-mutation.


In patients with borderline resectable NSCLC including oligometastatic disease, induction IO resulted in a high rate of curative treatment with promising survival. Resected patients achieved a high rate of prognostically favorable pathological response.

Clinical trial identification


Legal entity responsible for the study

The authors.


Has not received any funding.


M. Faehling: Financial Interests, Personal, Advisory Board: AstraZeneca, Roche, BMS, MSD; Financial Interests, Institutional, Invited Speaker: MSD, AstraZeneca, Gilead, Roche, Daiichi Sankyo, Mirati, Revolution Medicines. S. Kramberg: Financial Interests, Personal, Invited Speaker: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.